A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know
West executed a sale under a pre-established Rule 10b5-1 trading plan, reducing her direct stake by 8% while retaining 34,981 shares worth roughly $1.8 million.
Nadja West, a Tempus AI director, sold shares of the company's Class A Common Stock on August 14. According to a recent SEC filing, she sold 3,000 shares at $53.90 per share, with a transaction value of $161,700. The stock's market price closed at $52.10 that day. Tempus AI, headquartered in Chicago, is a healthcare technology firm with a market value of $9 billion and around 3,800 employees.
The company's annual revenue for the trailing twelve months (TTM) was $1.4 billion, and it is currently operating at a net loss due to heavy investments in platform development and market expansion. Tempus AI's unique selling point lies in its integrated platform that merges clinical workflow optimization with advanced diagnostic analytics, making it a full-service provider in precision medicine and genomic testing.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
